Clinical Trial

A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD. The study will determine the short-term and long-term safety and tolerability of L606 in this patient population.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2020-12-27; most recent amendment 2026-03-30.
Status change: Recruiting → Active, Not Recruiting 2024-10-08
Status change: Not Yet Recruiting → Recruiting 2021-11-10
Trial Details
NCT Number NCT04691154
Lead Sponsor Liquidia Technologies, Inc.
Collaborators: PPD Development, LP
Conditions Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases
Enrollment 28 participants
Start Date 2021-08-01
Primary Completion 2025-03-20 (estimated)
Study Completion 2031-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-01